Daily Endocrinology Research Analysis
Analyzed 77 papers and selected 3 impactful papers.
Summary
Today’s top endocrinology papers span large-scale metabolomics for type 2 diabetes risk, perioperative implications of GLP‑1 receptor agonists on gastric emptying, and a new radiographic invasiveness score for pituitary adenomas. Collectively, they advance predictive biomarkers, refine procedural risk management, and improve surgical planning.
Research Themes
- Metabolomics-driven risk prediction for type 2 diabetes
- Perioperative management in GLP-1 receptor agonist users
- Methodological innovation in pituitary adenoma invasiveness grading
Selected Articles
1. Plasma Metabolite Associations for Risk and Laboratory Measures of Type 2 Diabetes in a Large-Scale Finnish Prospective Cohort.
In a 10,163-man prospective cohort, 193 plasma metabolites were associated with prevalent T2D, including 71 not previously reported; 88 of these also predicted incident T2D over 13.6 years. Eighty-one metabolites partially mediated links between lifestyle risk factors and T2D onset, and adding significant metabolites improved predictive models.
Impact: This large, well-characterized cohort links specific metabolites to both prevalent and incident T2D and delineates mediating pathways from lifestyle risk factors, advancing biomarker discovery and mechanistic understanding.
Clinical Implications: Metabolite panels may enhance early risk stratification and personalized prevention strategies for T2D, pending external validation in women and diverse populations and translation into clinical workflows.
Key Findings
- Identified 193 plasma metabolites associated with prevalent T2D at baseline; 71 were previously unreported.
- Eighty-eight of these metabolites were associated with incident T2D over a mean 13.6-year follow-up.
- Eighty-one metabolites partially mediated associations between five lifestyle risk factors and T2D onset.
- Including significant metabolites improved predictive ability for future T2D.
- Metabolites showed broad correlations with T2D-related laboratory measures (0–24 per metabolite; mean 10.2).
Methodological Strengths
- Large, well-phenotyped prospective cohort with long-term follow-up (mean 13.6 years).
- Comprehensive metabolomic profiling (979 named metabolites) with rigorous multivariable and mediation analyses.
Limitations
- Participants were Finnish men only; generalizability to women and other populations remains to be established.
- Observational mediation relies on assumptions; causal pathways are not proven.
Future Directions: Validate findings in women and diverse populations, integrate metabolomics with genetics and proteomics, and test whether metabolite-informed interventions can reduce T2D incidence.
OBJECTIVE: We aimed to identify plasma metabolites significantly associated with existing type 2 diabetes (T2D), further characterize their associations with T2D-related laboratory measures and lifestyle-related risk factors, and evaluate their potential mediating and predictive roles for incident T2D. RESEARCH DESIGN AND METHODS: We performed metabolomic profiling in 10,163 Finnish men in the Metabolic Syndrome in Men (METSIM) study at baseline. Of these participants, 1,412 had prevalent T2D and 1,234 developed incident T2D during an average follow-up period of 13.6 years. We tested for associations of 979 named metabolites with prevalent T2D. For significant metabolites, we further evaluated their associations with 24 T2D-related laboratory measures of five groups and five T2D lifestyle-related risk factors. We performed an exploratory mediation analysis to examine the mediation effects of metabolites on incident T2D for the five risk factors. We evaluated metabolite associations with incident T2D and built exploratory metabolite predictive models for incident T2D. RESULTS: We identified 193 plasma metabolites significantly associated with prevalent T2D at baseline, including 71 previously unreported. Of these 193 metabolites, 88 were associated with incident T2D. In participants with prevalent T2D, the 193 metabolites showed associations with zero to 24 (mean 10.2) T2D-related laboratory measures. Eighty-one metabolites partially mediated the associations of the five risk factors with T2D onset under standard mediation assumptions. The significant metabolites showed improved predictive ability for future T2D. CONCLUSIONS: This study identifies T2D plasma metabolic biomarkers for further investigation in women and other populations. The findings enhance our understanding of T2D biology.
2. Prevalence and predictors of residual gastric content in patients with type 2 diabetes on GLP-1 receptor agonists: A prospective observational study.
In a prospective cohort of 390 inpatients with T2D, GLP‑1 RA use was associated with significantly higher odds of increased residual gastric content despite standard fasting (IPTW-adjusted OR 2.52). Diabetic retinopathy and kidney disease independently identified a high-risk microvascular phenotype, and each day since last GLP‑1 RA dose reduced risk by 23%.
Impact: Findings directly inform perioperative management as GLP‑1 RAs are widely used; they quantify risk, identify vulnerable phenotypes, and offer a practical, timing-based mitigation lever.
Clinical Implications: Standard fasting may be insufficient in GLP‑1 RA users, especially with retinopathy or kidney disease. Consider individualized pre-procedural assessment and dose timing adjustments (longer withholding intervals) in high-risk patients.
Key Findings
- After propensity score matching, increased RGC was more prevalent in GLP‑1 RA users vs non-users (53.3% vs 32.1%; p<0.001).
- GLP‑1 RA use independently associated with increased RGC (IPTW-adjusted OR 2.52; 95% CI 1.84–3.45).
- Diabetic retinopathy (OR 1.84) and diabetic kidney disease (OR 1.67) were independent risk factors.
- Among GLP‑1 RA users, each additional day since the last dose reduced odds of increased RGC by 23% (adjusted OR 0.77).
Methodological Strengths
- Prospective single-centre cohort with predefined fasting conditions and robust causal-inference adjustments (PSM and IPTW).
- Clear, clinically interpretable effect sizes and identification of phenotype-specific risk.
Limitations
- Single-centre design limits generalizability; external validation is needed.
- Observational study; aspiration events and clinical outcomes were not reported.
Future Directions: Multicentre validation, integration with gastric assessment protocols, and trials testing dosing-withhold strategies to reduce aspiration risk.
AIMS: To assess the prevalence and risk factors of increased residual gastric content (RGC) under fasting conditions in patients with type 2 diabetes mellitus (T2DM) treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), providing evidence for peri-procedural medication management. MATERIALS AND METHODS: This single-centre prospective cohort study enrolled inpatients with T2DM at the Endocrinology Department of Ningbo No.2 Hospital between April and December 2024. Patients aged 18-80 years with BMI <40 kg/m RESULTS: Of 390 patients included (237 [60.8%] male), 224 (57.4%) were GLP-1 RA users. After propensity score matching, the prevalence of increased RGC remained significantly higher in GLP-1 RA users compared with non-users (53.3% vs. 32.1%; p < 0.001). In multivariate logistic regression adjusted by inverse probability of treatment weighting (IPTW), GLP-1 RA use was robustly associated with increased RGC (OR 2.52; 95% CI 1.84-3.45). Notably, diabetic retinopathy (OR 1.84; 95% CI 1.14-2.99) and diabetic kidney disease (OR 1.67; 95% CI 1.17-2.39) emerged as independent risk factors, identifying a high-risk microvascular phenotype. Furthermore, among GLP-1 RA users, each additional day since the last GLP-1 RA dose reduced the odds of increased RGC by 23% (adjusted OR 0.77; 95% CI 0.65-0.90). CONCLUSIONS: GLP-1 RA therapy is a potent, independent driver of significant gastric retention in patients with T2DM, persisting despite standard fasting. Crucially, the presence of diabetic retinopathy or nephropathy identifies a "double-hit" high-risk phenotype, where pharmacological delay interacts with microvascular burden. These findings suggest that current fasting protocols may be insufficient for these patients, necessitating individualized preoperative assessment based on microvascular status and dosing timing.
3. The INVasiveness in Pituitary ADEnomas Score: Development and Validation of a Novel Radiographic Grading Scale for Pituitary Adenoma Invasion.
The INVADE score is a novel, global radiographic grading of pituitary adenoma invasiveness with strong inter-rater (κ=0.725) and near-perfect intra-rater (κ=0.836) reliability. High INVADE scores predicted lower volumetric extent of resection and functional status, outperforming the Knosp classification.
Impact: Provides a standardized, reliable, and more predictive metric for surgical planning and research stratification in pituitary adenomas, addressing limitations of existing scales.
Clinical Implications: INVADE may guide preoperative risk stratification and surgical strategy, improving prognostication and enabling harmonized reporting across centers.
Key Findings
- Strong inter-rater reliability for the overall INVADE score (weighted κ=0.725) and near-perfect intra-rater reliability (κ=0.836).
- High INVADE scores were associated with lower volumetric extent of resection (79.1% vs 96.0%, P<.001).
- High INVADE scores were more likely in functional adenomas (P=.020) and outperformed the Knosp classification.
Methodological Strengths
- Blinded multi-rater assessment with weighted Cohen’s kappa for both global and component-level reliability.
- Predictive validity demonstrated against volumetric extent of resection and functional status.
Limitations
- Limited sample size (40 scans) and single-set rater cohort; external, prospective validation is needed.
- Primarily imaging-based endpoints; broader linkage to long-term clinical outcomes remains to be shown.
Future Directions: Prospective, multicentre validation; integration with molecular signatures; testing clinical utility for surgical navigation and outcome prediction.
BACKGROUND AND OBJECTIVES: A comprehensive, linear, and reliable radiographic scale for pituitary adenoma invasiveness that accounts for tumor invasion into multiple anatomic structures is needed to correlate with surgical outcomes and genetic and molecular signatures. In this study, we present the INVasiveness in pituitary ADEnomas (INVADE) score and evaluate its inter-rater and intra-rater reliability. We evaluated the INVADE score to predict the extent of resection (EOR) and functional status. METHODS: Six neurosurgeons or neuroradiology attending physician raters each individually scored 40 unique MRI and computed tomography scans of biopsy-proven pituitary adenomas. Inter-rater reliability was calculated for the total score and for each component of the score. After a 4-week washout period, 3 raters rescored each set of MRI and computed tomography scans and intra-rater reliability was evaluated. Inter-rater and intra-rater reliability values were determined using weighted Cohen's κ coefficients. Tumors were dichotomized into high (3-6) and low (0-2) INVADE scores, and the EOR and functional status were compared. RESULTS: Overall, the inter-rater reliability of the INVADE score was strong (κ = 0.725; 95% CI, 0.612-0.824). Regarding the individual components of the score, the reliability for arachnoid, cavernous sinus, and sellar face/floor invasion was strong, whereas the reliability for brain parenchyma, clivus, and lateral sphenoid bone invasion was moderate. Intra-rater reliability was nearly perfect (κ = 0.836; 95% CI, 0.713-0.909). Tumors with high (3-5) INVADE scores had significantly lower volumetric EOR (79.1% vs 96.0%, P < .001) and were more likely functional (P = .020) and outperformed the Knosp score. CONCLUSION: We present a novel scale to assess global radiographic invasiveness in pituitary adenomas. The INVADE score demonstrated strong inter-rater reliability and nearly perfect intra-rater reliability. High INVADE scores correlated with significantly lower volumetric EOR. Our results suggest that the INVADE score may be useful for future clinical and research applications.